ArticleBreast care (Basel, Switzerland)2023
Ten-Year Survival of Breast Cancer in Iran: A National Study (Retrospective Cohort Study).
Article in Breast care (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Design and Usability Evaluation of a Smartphone Application for Postoperative Self-Management in Breast Cancer Patients.Cancer medicine · 2026Article
- Improving Breast Cancer Outcomes Through Quality Care: Call to Action for the Implementation of the Breast Cancer Care Quality Index (BCCQI).International journal of environmental research and public health · 2026Article
- Characteristics of Breast Cancer Patients in Northeastern Iran: A Retrospective Cohort Study.Breast cancer : basic and clinical research · 2026Article
- Lobular breast cancer and prognosis: what should we tell patients?Frontiers in oncology · 2026Review
- Preparedness for caregiving among caregivers of breast cancer patients and its association with health literacy and caregiving competence.Scientific reports · 2025Article
- Survival Rate of Breast Cancer and Related Factors in Iran: A 27-Year Follow-Up.Iranian journal of public health · 2025Article
- The patterns and spectrum of BRCA1 and BRCA2 mutations in Iranian breast and ovarian cancer patients.Familial cancer · 2025Article
- Application of machine learning in breast cancer survival prediction using a multimethod approach.Scientific reports · 2024Article
- Risk and prognosis of second cutaneous melanoma after radiotherapy for breast cancer: A population-based analysis.Biomolecules & biomedicine · 2024Article
- Article
- Long-Term Outcomes of Breast Cancer Patients Receiving Levobupivacaine Wound Infiltration or Diclofenac for Postoperative Pain Relief.Pharmaceutics · 2023Article
- Time-related survival prediction in molecular subtypes of breast cancer using time-to-event deep-learning-based models.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to estimate the 5- and 10-year survival rates of breast cancer in Iran. Methods: This retrospective cohort study was performed in 2019 on breast cancer patients registered in the national cancer registry system of Iran during 2007-2014. The patients were contacted to collect their information and status (alive or dead). Age and pathological type of tumor were categorized into five groups, and the place of residence was divided into 13 regions. The Kaplan-Meier method and the Cox proportional hazards model were used for data analysis. Results: A total of 87,902 patients were diagnosed with breast cancer during the study, 22,307 of whom were followed-up. The 5- and 10-year survival rates of the patients were 80% and 69%, respectively. The mean age of the patients was 50.68 ± 12.76 years (median age, 49 years). About 2.3% of the patients were male. The 5- and 10-year survival rates were 69% and 50% in men, respectively. The highest survival rate was reported in the age group of 40-49 years, and the lowest rate was found in the age group of ≥70 years. Of all pathological types, 88% were found in the invasive ductal carcinoma group; the highest survival rate was reported in the noninvasive carcinoma group. The highest survival rate was reported in the Tehran region and the lowest in the Hamedan region. Based on the results, the Cox proportional hazards model, sex, age group, and pathological type were statistically significant differences. Conclusion: This nationwide study performed on breast cancer patients indicated an improvement in the overall survival rate of these patients over the past years (the 5-year survival rate increased from 71% in 2011 to 80% in the present study), which might be attributed to advances in cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.